AI assistant
Sending…
LEXICON PHARMACEUTICALS, INC. — Director's Dealing 2022
Feb 14, 2022
32814_dirs_2022-02-14_0c40da9a-48c5-42b8-93ad-3e02a4d7beeb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK: 0001062822
Period of Report: 2022-02-10
Reporting Person: McDermott Wendy (VP, Human Resources)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-10 | Stock Option (Right to Buy) | $3.20 | A | 170500 | Acquired | 2032-02-10 | Common Stock (170500) | Direct |
| 2022-02-10 | Restricted Stock Units | $ | A | 56830 | Acquired | Common Stock (56830) | Direct |
Footnotes
F1: Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.
F2: Each restricted stock unit represents a contingent right to receive one share of common stock.
F3: Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.